Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
One of the puzzling observations from anti–amyloid-β therapeutic trials for Alzheimer disease (AD) has been that treated arms fail to show preservation of brain volume. In this issue of Neurology ®, Alves et al.1 presented a meta-analysis of anti–amyloid-β therapies and show that the agents do not slow the rate of brain volume loss. Depending on the class of drug, these new agents can even accelerate loss of whole-brain and hippocampal volume and increase ventricular volume. This association has been seen with some of the beta-secretase inhibitors and with several of the antiamyloid monoclonal antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Cited by
Alzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Jeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
“In treatment with aducanumab, lecanemab, or donanemab, acceleration of brain volume loss has been reported, which is attributed to amyloid removal [41-43].”
Background
Metadata
- Authors
- Barkhof, F., & Knopman, D. S.
- Venue
- Neurology
- Published
- 2023-05-16
- Volume
- 100
- Issue
- 20
- Pages
- 941-942
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4360992211
- Cited by
- 38
- References
- 1
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy? https://app.cochat.ai/papers/10.1212/wnl.0000000000207268
- The paper
- Barkhof, F., & Knopman, D. S. (2023). Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy? Neurology. https://doi.org/10.1212/wnl.0000000000207268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.